EndoCyclic Therapeutics is an Irvine, California-based biopharmaceutical company pioneering innovative, non-hormonal therapeutics and diagnostics for women’s health and oncology.

We are dedicated to revolutionizing endometriosis care with the development of the first potential disease-modifying therapeutic, ENDO-205, designed to eliminate lesions and associated symptoms – addressing a condition that affects over 190 million women globally.

Our precision peptide technology enables targeted delivery, reducing off-target side effects and offering a non-invasive alternative to traditional diagnostic methods. We are also advancing an investigational imaging diagnostic agent, FemLUNA, for endometriosis and other cancers, representing a new era of precision treatment.

EndoCyclic Therapeutics is committed to transforming patient lives through groundbreaking solutions in women’s health and oncology.

ENDO-205 | EndoCyclic Therapeutics

Service description

EndoCyclic Therapeutics Irvine, United States (US)

Price: N/A

EndoCyclic Therapeutics
Irvine, United States (US)